Oct
2026
Fiera Milano, Italy
Visit us
stand 6F58, Contract Manufacturing & Services
Corden Pharma International GmbH
Exhibitor at CPHI Milan 2026
About Us
Categories
-
Country/Region:Germany
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Contact info
-
-
-
Otto-Hahn-Strasse, 68723, Plankstadt, Germany
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 6F58, Contract Manufacturing & Services
Products Featured at CPHI Milan 2026
-
Product API Crystallization Capabilities & Services
Identifying, developing, and obtaining the best crystalline form of an API is crucial in drug development. It has a significant impact on the drug product quality, the effectiveness of the drug product formulation and, in particular, the bioavailability of the finished dosage form. At CordenPharma we have ... -
Product Bioavailability Enhancement
Solubility is one of the key attributes of a drug candidate and one of the biggest challenges in drug development. Approximately 70-90% of New Molecular Entities (NMEs) in today’s drug pipeline are poorly soluble, which complicates delivery, resulting in poor bioavailability. The majority of these NMEs are... -
Product CordenPharma Oligonucleotides Platform
Your Expert Partner for Oligonucleotide APIs - Process Development & Small-scale: scale-up to 10 mmol per run (small-scale equipment can also support early-stage supply) - Scale-up & Small to Medium-scale: scale-up to 100 mmol per run (supported by OligoPilotTM equipment) - Large-Scale Oligonucleotide Proc... -
Product CordenPharma's Early-Phase Peptide Centre of Excellence
In addition to the largest worldwide capacity of commercial SPPS peptide production up to batch sizes exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 Metric Tons of Peptide, CordenPharma's multi-pronged approach to becoming the #1 peptide CDMO supplier extends to small-scale capabilities,... -
Product Drug Product Services
As your CDMO partner, we provide development and manufacturing services for oral solid dose (OSD), non-sterile liquid and rectal dosage forms, and parenteral dosage forms for all phases of clinical development through commercialization. This broad spectrum of capabilities also allows formulations of highl...
